Related Experiment Video
Updated: Jun 14, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Is there a future for direct renin inhibitors?
Kunal Chaudhary1, Ravi Nistala, Adam Whaley-Connell
1Harry S Truman VA Medical Center, Columbia, MO 65211, USA. chaudharyk@health.missouri.edu
Expert Opinion on Investigational Drugs
|April 13, 2010
Summary
Direct renin inhibitors (DRIs) like aliskiren offer a novel approach to managing hypertension by directly targeting renin. Preliminary data suggests aliskiren may improve cardiovascular and kidney disease outcomes, potentially offering better tolerability in combination therapies.
Area of Science:
- Cardiovascular Pharmacology
- Renal Medicine
- Hypertension Therapeutics
Background:
- The renin-angiotensin-aldosterone system (RAAS) critically regulates blood pressure and electrolyte balance.
- Dysregulated RAAS activation is implicated in hypertension, cardiovascular disease (CVD), and chronic kidney disease (CKD).
- Current RAAS inhibitors (ACEi, ARB) can lead to incomplete suppression and compensatory renin upregulation.
Purpose of the Study:
- To review the preclinical and clinical knowledge of direct renin inhibitors (DRIs).
- To evaluate the antihypertensive efficacy of DRIs concerning cardiovascular and renal risk.
- To explore aliskiren's potential as a novel therapeutic intervention for RAAS suppression.
Main Methods:
- Review of current scientific literature on DRIs.
- Analysis of preclinical and clinical data regarding DRIs' efficacy and safety.
- Examination of recent clinical trial outcomes (2007-2009) for aliskiren.
Main Results:
- Direct renin inhibitors (DRIs) provide a mechanism to directly inhibit the rate-limiting step of the RAAS.
- Aliskiren demonstrates antihypertensive efficacy and potential benefits for CVD and CKD.
- Combination therapy with aliskiren may offer improved tolerability compared to ACEi-ARB combinations.
Conclusions:
- Aliskiren is an effective antihypertensive agent with preliminary evidence of cardiovascular and renal benefits.
- Further research is necessary to confirm aliskiren's impact on hard clinical endpoints in CVD and CKD.
- DRIs represent a promising therapeutic strategy for more complete RAAS suppression.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...